Introduction
============

The GOLD 2017 strategy document recommends that the pharmacological management of COPD patients be based on the risk of future exacerbations and the severity of symptoms.[@b1-copd-12-3263] Forced expiratory volume in 1 second (FEV~1~) has been removed as a criterion for identifying patients at high risk of exacerbation for pharmacological treatment decisions. A threshold of two exacerbations requiring antibiotics and/or corticosteroids or one hospitalization in the previous year is used as the sole criterion to identify patients at high risk of future exacerbations.

The ECLIPSE study showed that COPD patients with a history of one compared to zero exacerbations in the previous year were at increased risk of future exacerbations (OR 2.24, *P*\<0.001).[@b2-copd-12-3263] Other COPD cohorts have confirmed the increase in risk in patients with a history of one exacerbation in the previous year,[@b3-copd-12-3263] supporting the case for treatment strategies to reduce future exacerbation risk in this subgroup of patients. However, GOLD has used two or more exacerbations, "frequent exacerbators", as a threshold for preventive treatment, due to a greater level of risk (OR 5.72, *P*\<0.001 in the ECLIPSE study).[@b2-copd-12-3263]

In line with the previous 2011 version, GOLD 2017 still recommends inhaled corticosteroid (ICS)--long acting β-agonist (LABA) combination inhalers for high-risk patients, ie, groups C and D,[@b1-copd-12-3263] but not for patients at lower risk (groups A and B). However, clinical trials investigating the effects of ICS-LABA combinations on exacerbation prevention have often used inclusion criteria of FEV~1~ \<50% predicted and one or more exacerbations in the previous year.[@b4-copd-12-3263]--[@b6-copd-12-3263] Under the GOLD 2011 recommendations, most enrolled in these studies were high-risk patients because of low FEV~1~, as only a minority had had two or more exacerbations in the previous year. However, the removal of FEV~1~ from the risk assessment means that the patients enrolled in previous ICS/LABA clinical trials are a mixture of high- and low-risk patients using the GOLD 2017 definition.

The FORWARD study was a randomized, double-blind, parallel-group trial that compared 48 weeks' treatment with extrafine beclomethasone dipropionate (BDP) 100 μg plus formoterol fumarate (FF) 6 μg with pressurized metered-dose inhaler (two inhalations twice daily) versus FF 12 μg with pressurized metered-dose inhaler (one inhalation twice daily).[@b4-copd-12-3263] Severe COPD patients (FEV~1~ \<50% predicted) with one or more exacerbations in the previous year were recruited. An important element of the design was that patients who had previously been taking the long-acting muscarinic antagonist (LAMA) tiotropium before screening were allowed to continue this treatment during the run-in period and after randomization to either BDP-FF or FF. This study demonstrated a significant and clinically relevant[@b7-copd-12-3263] reduction in the rate of moderate--severe exacerbations (31% reduction using negative binomial model) and lung function improvement with BDP-FF compared to FF treatment. Moderate exacerbations were defined as events requiring treatment with oral CSs and/or antibiotics, while severe events required hospitalization.

The majority of patients in the FORWARD study did not meet the GOLD 2017 criteria for high exacerbation risk, as they had had one exacerbation in the previous year. While ICS-LABA treatments are not recommended by GOLD 2017 for such patients, the known increase in exacerbation risk in these patients indicates that treatments designed to prevent exacerbations should be considered. We conducted a post hoc analysis of the effects of extrafine BDP-FF in patients with one exacerbation in the previous year in the FORWARD study. We focused on patients with a higher level of symptoms who would be classified as GOLD B patients.

Materials and methods
=====================

The full design and results of the study have been published (registered at [ClinicalTrials.gov](http://ClinicalTrials.gov), NCT00929851).[@b4-copd-12-3263] The study was approved by the ethics committee or institutional review board at each site ([Tables S1](#SD1-copd-12-3263){ref-type="supplementary-material"}[](#SD2-copd-12-3263){ref-type="supplementary-material"}--[S3](#SD3-copd-12-3263){ref-type="supplementary-material"}) and was done in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice (ICH/CPMP/135/95), and applicable local regulations. All patients provided written informed consent before any study-related procedure.

The COPD assessment test (CAT) and modified Medical Research Council (mMRC) scores were not collected at screening. We used the St George's Respiratory Questionnaire (SGRQ) to identify patients with greater symptoms using a threshold of ≥25 as previously described.[@b8-copd-12-3263] This was called analysis 1. To provide confirmation of these results, we performed analysis 2, using items regarding breathlessness within the SGRQ that identify patients with dyspnea corresponding to mMRC scores ≥2. The SGRQ questions were those about "what activities usually make subjects feel breathless" and those about "how activities may be affected by their breathing". Answers indicating greater dyspnea than others of the same age or dyspnea while walking on level ground/needing to rest were used to identify dyspnea corresponding to mMRC scores ≥2.

Information on the number of exacerbations (requiring oral CSs and/or antibiotics) in the last year was available for each patient, but the specific number of these events resulting in hospitalization was not registered. A threshold of two exacerbations was used to define high-risk patients (GOLD C or D). Using the GOLD 2017 classification, 716 patients in analysis 1 (60.4% of 1,186 patients included in the intention-to-treat population) were categorized as GOLD B, with 87 (7.3%), 25 (2.1%), and 313 (26.4%) categorized as GOLD A, C, and D, respectively, while for 45 patients the category could not be assessed. There were similar proportions for analysis 2: 662 patients (55.8%) were GOLD B, with 160 (13.5%), 44 (3.7%), and 301 (25.4%) categorized as GOLD A, C, and D, respectively, while for 19 patients the category could not be assessed. In each GOLD group, the same approach for statistical analysis as originally used in the overall population was followed. The number of COPD exacerbations and predose morning FEV~1~ were analyzed using a negative binomial model and a mixed model for repeated measures, respectively.[@b4-copd-12-3263] Stratified analyses according to the concomitant use of tiotropium were additionally performed.

Results
=======

For analysis 1, in GOLD B patients, adjusted exacerbation rates were 0.67 and 1.04 events/patient/year with BDP-FF and FF, respectively ([Figure 1](#f1-copd-12-3263){ref-type="fig"}), with an adjusted RR of 0.65 (*P*\<0.001) in favor of BDP-FF ([Table 1](#t1-copd-12-3263){ref-type="table"}). Similar results were obtained for patients using tiotropium or no tiotropium (adjusted RR 0.54 and 0.76, respectively), although the latter was not statistically significant (*P*=0.119). Analysis 2 in GOLD B patients gave similar results: adjusted exacerbation rates were 0.71 and 1.09 events/patient/year with BDP-FF and FF, respectively ([Figure 2](#f2-copd-12-3263){ref-type="fig"}), with an adjusted RR of 0.65 (*P*\<0.001) in favor of BDP-FF. Effects of tiotropium versus no tiotropium use gave adjusted RRs of 0.58 and 0.7, respectively, with the latter again not reaching statistical significance (*P*=0.054).

For analyses 1 and 2, in GOLD B patients the adjusted mean difference in predose FEV~1~ at week 12 was 69 mL (*P*\<0.001) in favor of BDP-FF compared to FF. This significant difference between treatments was present in both analyses, irrespective of tiotropium use. Analyses for the overall population and GOLD D patients are shown in [Table 1](#t1-copd-12-3263){ref-type="table"} and [Figures 1](#f1-copd-12-3263){ref-type="fig"} and [2](#f2-copd-12-3263){ref-type="fig"}. The number of exacerbations/patient/year was higher in GOLD D compared to GOLD B patients, but treatment effects were similar in these two groups for both FEV~1~ changes and exacerbation rate reduction.

Discussion
==========

This post hoc analysis focused on COPD patients with one exacerbation in the previous year and a high burden of symptoms. There was a 35% reduction in exacerbation rate with ICS-LABA compared to LABA. GOLD B consists of patients with no or one exacerbation in the previous year. The future exacerbation risk is higher in the subgroup with one event in the previous year,[@b3-copd-12-3263],[@b4-copd-12-3263] and we provide evidence for the efficacy of ICS-LABA over LABA alone in these patients.

It has been shown that some GOLD B patients are at high risk of rapid disease progression.[@b9-copd-12-3263] The factors known to be associated with a greater decline in lung function include current smoking, emphysema, and exacerbations.[@b10-copd-12-3263] GOLD B is clearly a heterogeneous patient group, and the data presented here support the use of ICS-LABA in a subset of GOLD B.

We used the SGRQ to identify patients with a higher symptom burden and categorized these patients as GOLD B. The SGRQ threshold of 25 has been used previously for this purpose.[@b8-copd-12-3263] We realize that this methodology does not strictly match the GOLD B definition based on CAT or mMRC scores, but it is a recognized way to identify patients with a greater level of symptoms. We performed an analysis using specific questions within the SGRQ to identify patients with greater breathlessness. The two different analyses provided very similar results.

Although we knew how many overall exacerbations occurred in the previous year, the number of these that required hospitalization was not known. It is thus likely that some patients categorized as GOLD B here were really GOLD D patients. These were likely to be only a small proportion of individuals, as hospitalizations occur in a minority of exacerbations. We suggest that this reclassification would not have altered the results, as the results in GOLD B and D were similar.

This post hoc analysis has limitations in terms of the definition of GOLD B patients. Furthermore, the smaller sample sizes of the subgroups analyzed results in a decrease in statistical power. Caution must thus be applied to the interpretation of these data. Nevertheless, these results provide a level of evidence to debate the place of ICS-LABA treatment for patients with a history of one exacerbation.

The FORWARD study was conducted in severe COPD patients being followed up, with approximately half taking tiotropium. A subanalysis of GOLD B patients according to concurrent tiotropium use showed efficacy for additional ICS therapy on exacerbations and lung function in both patients using a LABA alone and those using a LABA plus LAMA. Exacerbation rate reductions of 24% and 30% (analyses 1 and 2, respectively) due to ICS in patients not using tiotropium were not statistically significant (*P*=0.119 and *P*=0.054), and we suggest this was due to a relatively small sample size in a subgroup. Nevertheless, the overall pattern of results on exacerbations and FEV~1~ in GOLD B patients with one exacerbation in the previous year support the addition of an ICS to either LABA monotherapy or LABA plus LAMA treatment. Indeed, the significant exacerbation reduction in both analyses for patients taking triple therapy (BDP-FF plus tiotropium) versus LABA-LAMA treatment (FF plus tiotropium) indicates the potential effectiveness of triple therapy in a subset of GOLD B patients.

GOLD recognizes that some of its recommendations lack evidence and may require refinement or alteration as new evidence becomes available.[@b1-copd-12-3263],[@b11-copd-12-3263] We provide some evidence to debate the current use of inhaled medicines in patients with a history of one exacerbation, particularly those corresponding to the definition of GOLD B. We propose ICS-LABA treatment is a therapeutic option in the subset of GOLD B patients with one exacerbation in the previous year.

Supplementary materials
=======================

###### 

IECs/IRBs for recruitment wave 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                 Center, type                                                         IEC/IRB name, address
  ----------------------- -------------------------------------------------------------------- -------------------------------------------------------------------
  Austria                 CEC/LEC                                                              Gesundheitsdienst der Stadt Wien\
                                                                                               Ethikkommission der Stadt Wien\
                                                                                               8 Thomas-Klestil-Platz, Vienna 1030

  LEC Graz                Ethik-Kommission der Medizinischen Universität Graz\                 
                          2 Auenbruggerplatz, Graz 8036                                        

  LEC Linz                Ethikkommission am Krankenhaus der Elisabethinen\                    
                          2 Fadingerstrasse, Linz 4010                                         

  Czech Republic          CEC/LEC                                                              Etická Komise Fakultní Nemocnice v Motole\
                                                                                               84 V Úvalu, 150 06 Prague 5

  Germany                 CEC/LEC                                                              Landesamt für Gesundheit und Soziales

  Berlin                  Ethik-Kommission des Landes Berlin\                                  
                          1 Fehrbelliner Platz, Berlin 10707                                   

  LEC Baden-Württemberg   Ethikkommission der Landesärztekammer Baden-Württemberg\             
                          Körperschaft des öffentlichen Rechts\                                
                          40 Jahnstrasse, Stuttgart 70597                                      

  LEC Bayern              Ethikkkommission der Landesärztekammer Bayern\                       
                          16 Mühlbauerstrasse München 81677                                    

  UK                      MREC                                                                 Professor Wellman\
                                                                                               Berkshire Research Ethics Committee\
                                                                                               Building L27, University of Reading, London Road, Reading RG1 5AQ

  MHRA                    Information Processing Unit\                                         
                          Area 6, Medicines & Healthcare Products Regulatory Agency, Market\   
                          Towers, 1 Nine Elms Lane, London SW8 5NQ                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** IECs, institutional ethics committees; IRBs, institutional review boards.

###### 

IECs/IRBs for recruitment wave 2

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country           Center, type                                                                               IEC/IRB name, address, chair (if applicable)
  ----------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------
  Argentina         CEC                                                                                        Comité Independiente de Etica para Ensayos en Farmacología Clínica -- FEFYM\
                                                                                                               \
                                                                                                               774 Pte JE Uriburu, 1 Piso -- CABA (C1027AAP)\
                                                                                                               Dr Luis Zieher

  320001            Comité de Docencia de Investigación\                                                       
                    French 2673, CABA, C1425AWC\                                                               
                    Clelia Haydee Magaril                                                                      

  32002             NA                                                                                         

  32003             Comité de Docencia e Investigación (CDI)\                                                  
                    San Martín de Tours 2926 -- CABA (1425)\                                                   
                    Dr Gustavo Badariotti                                                                      

  32004 IRB         Servicio de Investigación de Patologías Alérgicas del Instituto ABC\                       
                    2668 Salta, Rosario, Santa Fe (S2000JKR)\                                                  
                    Dr Alejandro Garcia                                                                        

  32005             NA                                                                                         

  Australia         36001                                                                                      Southern Adelaide Clinical Human Research Ethics Committee

  HREC              The Flats, G5 -- rooms 3 and 4\                                                            
                    Flinders Drive, Flinders Medical Centre, Bedford Park, SA 5042\                            
                    Professor Gordan                                                                           

  36002, 36003,     BellBerry Human Research Ethics Committee                                                  

  36004, 36005      229 Greenhill Road, Dulwich, SA 5065                                                       

  HREC              Brian Stoffell                                                                             

  Chile             152001                                                                                     Comité Etico Cientifico Servicio de Salud Oriente

  152002            364 Avenida Salvador, Providencia, RM                                                      

  CEC               Dr Andres Stuardo                                                                          

  152003            Comité Etico Cientifico Servicio de Salud Metropolitano Sur                                

  CEC               3453 Avenida Santa Rosa, RM\                                                               
                    Veronica Rivera                                                                            

  152006            Comité Etico Cientifico Servicio de Salud Coquimbo                                         

  CEC               795 Avenida Francisco Aguirre, La Serena\                                                  
                    Dr Buillermo Valdebenito                                                                   

  152009            Comité Etico Cientifico del Servicio de Salud del Maule                                    

  CEC               1 Norte -- 963, 2000 Edificio Centro, Piso Talca\                                          
                    Dr Rafael Muñoz                                                                            

  New Zealand       All sites                                                                                  Multi-region Ethics Committee\
                                                                                                               Ministry of Health, 133 Molesworth Street, PO Box 5013, Wellington 6145\
                                                                                                               Richman Wee

  South Africa      710001                                                                                     University of Cape Town, Health Science Faculty Research Ethics Committee\
                                                                                                               Room E52-24, Groote Schuur Hospital, Old Main Building Observatory, Cape Town 7925\
                                                                                                               Professor M Blockman

  710004            University of Stellenbosch, Faculty of Health Sciences Health Research Ethics Committee\   
                    PO Box 19063, Tygerberg 7505\                                                              
                    Dr J Meintjies                                                                             

  All other sites   Pharma Ethics\                                                                             
                    123 Amcor Road, Lytelton Manor, Pretoria 0157\                                             
                    Dr C Duvenage                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** IECs, institutional ethics committees; IRBs, institutional review boards.

###### 

IECs/IRBs for recruitment wave 3

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country           Center, type                                                                                    IEC/IRB name, address, chair (if applicable)
  ----------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Bulgaria          MEC/CEC                                                                                         Ethics Committee for Multicenter Clinical Trials\
                                                                                                                    8 Damian Gruev Street; Sofia 1303\
                                                                                                                    Dr Anastas Stoykov

  Czech Republic    MEC                                                                                             Multicentric Ethics committee\
                                                                                                                    84 FN Motol V Úvalu, 150 06 Prafue 5\
                                                                                                                    Chair Vratislav Smeihaus

  203007            Regionalní Etická Komise Nemocnice Tábor                                                        

  LEC               2000 Kapitána Jaroše, Tábor 390 03\                                                             
                    Ladislav Douda                                                                                  

  France            CEC                                                                                             Comité de Protection des Personnes\
                                                                                                                    CPP Ile de France III, Hopital Tarnier-Cochin\
                                                                                                                    89 rue d'Assas, Paris 75006\
                                                                                                                    Professor Boris Christoforov

  Germany           276001                                                                                          Landesamt für Gesundheit und Soziales

  276016            Ethik-Kommission des Landes Berlin\                                                             
                    1 Fehrbelliner Platz Berlin 10707\                                                              
                    Dr Hans-Herbert Fulle                                                                           

  276013            Ethikkkommission der Landesärztekammer Sachsen                                                  

  276014            16 Schützenhöhe, Dresden 01099                                                                  

  276015            Professor Habil R Haupt                                                                         

  276005            Ethikkommission der Landesärztekammer Baden-Württemberg\                                        
                    Körperschaft des öffentlichen Rechts\                                                           
                    40 Jahnstrasse, Stuttgart 70597\                                                                
                    Dr Georg Hook                                                                                   

  276016            Ethikkommission der Ärztekammer Niedersachsen\                                                  
                    20 Berliner Allee, Hannover 30175\                                                              
                    Dr Gisbert Voigt                                                                                

  276012            Ethikkommission der Ärztekammer Westfalen-Lippe und der Medizinischen Fakultät der\             
                    Westfälischen Wilhelms-Universität\                                                             
                    210--214 Gartenstrasse, Münster 48147\                                                          
                    Professor Hans-Werner Bothe\                                                                    

  Hungary           All sites                                                                                       Egeszsegugyi Tudomanyos Tanacs\
                                                                                                                    Klinikai Farmakologiai Etikai Bizottsaga\
                                                                                                                    6--8 Ulitsa Arany János, Budapest 1051\
                                                                                                                    Dr Zsussanna Furst

  Italy             380001                                                                                          Comitato per la Sperimentazione Clinica dei Medicinali dell'Azienda Ospedaliero\
                                                                                                                    Universitaria Pisana di Pisa\
                                                                                                                    67 Via Roma, Pisa 56126

  380002            Comitato Etico per la Sperimentazione Clinica dei Medicinali dell'Azienda Ospedaliera\          
                    Universitaria Integrata di Verona\                                                              
                    1 Piazzale A Stefani, Verona 37126                                                              

  380003            Comitato Etico per la Sperimentazione Clinica dei Medicinali dell'Azienda Ospedaliero-\         
                    Universitaria Careggi di Firenze\                                                               
                    3 Largo Brambilla, Florence 50134                                                               

  380004            Comitato Etico Centrale Dell'Irccs Fondazione Salvatore\                                        
                    Maugeri Di Pavia, 4 via Salvatore Maugeri, Pavia 27100                                          

  The Netherlands   528001                                                                                          Medisch Ethische Toetsingscommissie Eindhoven\
                                                                                                                    Catharina-Ziekenhuis, Secretariaat METC\
                                                                                                                    2 Michelangelolaan 2, Eindhoven 5623\
                                                                                                                    MJH Stoffelen-Bruurs

  528002            Elkerliek Ziekenhuis, locatie Helmond\                                                          
                    METC, 25 Wesselmanlaan, Helmond 5707\                                                           
                    Mr Corbeij                                                                                      

  528003            METC Noord-Holland\                                                                             
                    Foreest Medical School\                                                                         
                    10 Nassauplein, Alkmaar 1815\                                                                   
                    B Blijham                                                                                       

  528004            Commissie WMO\                                                                                  
                    METC Noord-Holland, Foreest Medical School\                                                     
                    10 Nassauplein, Alkmaar 1815                                                                    

  Poland            All sites                                                                                       Komisja Bioetyczna\
                                                                                                                    Przy Okręgowej Izbie Lekarskiej w Warszawie\
                                                                                                                    18 Ulitsa Puławska, Warsaw 02-512\
                                                                                                                    Dr Marek Czarkowski

  Romania           All sites                                                                                       48 Aviator Sanatescu Street, Sector 1, Bucharest 011478\
                                                                                                                    Professor Sava Dumitrescu

  Spain             724002                                                                                          Dr F Javier Abad Gimeno\
                                                                                                                    Secretario del Comité Ético de Investigación\
                                                                                                                    Servicio de Farmacia, planta 1. Avenida Ramón y Cajal, Puerto de Sagunto, Valencia 46520

  724003            Comité Etico de Investigación Clínica del Hospital General\                                     
                    Universitario de Elche, Lorena Montolio Beltran\                                                
                    11 Camí de l'Almazara -- 3, Planta del Edificio Anexo II, Elche, Alicante 03203                 

  724004            Paz Lavilla/Emma Fernández de Uzquiano\                                                         
                    Hospital General Planta, 261 Paseo de la Castellana, Madrid 28046                               

  724005            Hospital Clinic i Provicial--Comité Etico de Investigación Clínica/Villarroel, 170 Sótano --\   
                    Escalera 6b, Barcelona 08036                                                                    

  Turkey            792-001                                                                                         Mersin University Health Research and Practice Hospital\
                                                                                                                    Ihsaniye Mah, 4903 Sokak -- 3 Necdet Unger Binası 3, Mersin 33079\
                                                                                                                    Professor Bahar Tunctan

  MEC               Ministry of Health\                                                                             
                    General Directorate of Pharmaceuticals and Pharmacy\                                            
                    2176 Söğütözü Mahallesi -- 5 PK\                                                                
                    Çankaya, Ankara 06520\                                                                          
                    Hilal Ilbars                                                                                    

  The UK            All sites                                                                                       Berkshire Research Ethics Committee\
                                                                                                                    Building L27, University of Reading, London Road, Reading RG1 5AQ
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** IECs, institutional ethics committees; IRBs, institutional review boards.
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![Adjusted exacerbation rates (per patient/year) for analysis 1 in GOLD B and GOLD D patients.\
**Abbreviations:** BDP-FF, beclomethasone dipropionate--formoterol fumarate; FF, formoterol fumarate.](copd-12-3263Fig1){#f1-copd-12-3263}

![Adjusted exacerbation rates (per patient/year) for analysis 2 in GOLD B and GOLD D patients.\
**Abbreviations:** BDP-FF, beclomethasone dipropionate--formoterol fumarate; FF, formoterol fumarate.](copd-12-3263Fig2){#f2-copd-12-3263}

###### 

COPD exacerbations and predose morning FEV~1~ at week 12: BDP-FF versus FF overall in GOLD B and D patients (intention-to-treat population)

  Group            n             COPD exacerbations: adjusted rate ratio[\*](#tfn1-copd-12-3263){ref-type="table-fn"}   Predose morning FEV~1~ (mL): adjusted mean difference[\*](#tfn1-copd-12-3263){ref-type="table-fn"}
  ---------------- ------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Overall**      1,186         0.69 (0.59--0.81; *P*\<0.001)                                                          69 (43--95; *P*\<0.001)
  Tiotropium       616 (51.9%)   0.68 (0.55--0.84; *P*\<0.001)                                                          48 (14--82; *P*=0.006)
  No tiotropium    570 (48.1%)   0.70 (0.56--0.88; *P*=0.003)                                                           90 (50--129; *P*\<0.001)
  **Analysis 1**                                                                                                        
  **GOLD B**       716 (60.4%)   0.65 (0.52--0.81; *P*\<0.001)                                                          69 (36--103; *P*\<0.001)
  Tiotropium       370 (31.2%)   0.54 (0.41--0.72; *P*\<0.001)                                                          52 (8--96; *P*=0.021)
  No tiotropium    346 (29.2%)   0.76 (0.54--1.07; *P*=0.119)                                                           85 (35--136; *P*=0.001)
  **GOLD D**       313 (26.4%)   0.75 (0.58--0.95; *P*=0.017)                                                           79 (33--125; *P*\<0.001)
  Tiotropium       169 (14.2%)   0.87 (0.62--1.22; *P*=0.419)                                                           66 (6--127; *P*=0.033)
  No tiotropium    144 (12.1%)   0.62 (0.44--0.87; *P*=0.006)                                                           90 (20--161; *P*=0.013)
  **Analysis 2**                                                                                                        
  **GOLD B**       662 (55.8%)   0.65 (0.52--0.82; *P*\<0.001)                                                          69 (36--102; *P*\<0.001)
  Tiotropium       359 (30.3%)   0.58 (0.43--0.78; *P*\<0.001)                                                          49 (6--92; *P*=0.027)
  No tiotropium    303 (25.5%)   0.70 (0.49--1.01; *P*=0.054)                                                           94 (42--145; *P*\<0.001)
  **GOLD D**       301 (25.4%)   0.74 (0.58--0.94; *P*=0.012)                                                           83 (37--128; *P*\<0.001)
  Tiotropium       163 (13.7%)   0.85 (0.6--1.21; *P*=0.366)                                                            61 (6--115; *P*=0.030)
  No tiotropium    138 (11.6%)   0.63 (0.46--0.86; *P*=0.004)                                                           101 (25--177; *P*=0.010)

**Notes:**

95% CI and *P*-value in parentheses. Number of COPD exacerbations and predose morning FEV~1~ analyzed using a negative binomial model and MMRM, respectively. Analysis 1 used SGRQ score ≥25 to identify patients corresponding to GOLD B. Analysis 2 used dyspnea questions within the SGRQ to identify patients corresponding to GOLD B.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; BDP-FF, beclomethasone dipropionate--formoterol fumarate; FF, formoterol fumarate; SGRQ, St George's Respiratory Questionnaire.
